PNC
VRTX icon

Park National Corp’s Vertex Pharmaceuticals VRTX Stock Holding History

Park National Corp’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,180
Closed -$527K – 396
2026
Q1 		$527K Buy
+1,180
New +$550K 0.02% 235

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
BHIA
Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return
CTB
Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
GIA
Gateway Investment Advisers Cincinnati, Ohio $10.1B AUM 40.26% 1-Year Est. Return
II
IFM Investors Melbourne, Australia $15.1B AUM 40.57% 1-Year Est. Return

Park National Corp's VRTX Position: Q2 2026 in Review

Park National Corp sold out of Vertex Pharmaceuticals (VRTX) in Q2 2026, closing a stake of 1,180 shares — an estimated $527K sold.

Park National Corp first reported a position in VRTX in Q1 2026 and held it in 1 quarter. The position peaked at $527K in Q1 2026. 334 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Park National Corp reported no remaining Vertex Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Park National Corp sold 1,180 Vertex Pharmaceuticals shares in Q2 2026, an estimated $527K.
  • Park National Corp first reported a position in Vertex Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Park National Corp's Vertex Pharmaceuticals position peaked at $527K in Q1 2026.
  • 334 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Park National Corp's 13F filing for Q2 2026, filed 15 Jul 2026.